Narrative review summarizes drug classes for coronavirus infection, including small molecules and Traditional Chinese Medicine.

This publication is a narrative review that explores various drug classes as potential treatments for coronavirus infection. The scope includes small-molecule drugs, macromolecular drugs, peptides, polymers, and Traditional Chinese Medicine, offering a broad overview of therapeutic approaches without focusing on specific interventions or comparators. As a narrative review, it does not involve systematic methods like meta-analysis, so it lacks pooled effect sizes, confidence intervals, or quantitative synthesis of outcomes.

The authors synthesize qualitative conclusions about the roles and mechanisms of these drug classes in managing coronavirus infection, drawing from existing literature. However, key details such as study populations, sample sizes, interventions, comparators, primary outcomes, follow-up duration, and safety data are not reported, limiting the ability to assess efficacy or safety directly. The review does not specify limitations or gaps acknowledged by the authors, and funding or conflicts of interest are not reported.

In terms of practice relevance, the review provides a conceptual framework for understanding diverse therapeutic options but does not offer specific clinical recommendations. Clinicians should view this as an informational summary rather than evidence-based guidance, pending more rigorous studies to validate any potential benefits or risks.